RESHAPE LIFESCIENCES INC (RSLS) 0.46 -0.03 (-6.12%)
0.46 -0.03 (-6.12%)
US76090R1014 - Common Stock - After market: 0.46 0 (0%)
Fundamental Rating
We assign a fundamental rating of 3 out of 10 to RSLS. RSLS was compared to 221 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of RSLS have multiple concerns. RSLS shows excellent growth, but is valued quite expensive already.
Profitability
Profitability Rating
RSLS has a Piotroski-F score of 4.00. This indicates an average health and profitability for RSLS.
The profitability ratios for RSLS are negative, so there is not much use analyzing them.
RSLS's Return On Assets of -138.09% is worse than the rest of the industry. The industry average Return On Assets is -17.37%. 97% of the industry peers have a better Return On Assets.
RSLS has a Profit Margin of -509.20%. This is below the industry average of -27.62%. 84% of the industry peers outperform RSLS.
VS Industry
ROA (-138.09%) VS Industry: 3% outperformed.
-910.41
181.55
Profit Margin (-509.2%) VS Industry: 16% outperformed.
-98,596.77
2,317.41
Valuation
Valuation Rating
When comparing the current price to the book value of RSLS, it is valued rather cheaply. It is trading at 0.22 times its book value.
Compared to an average industry price book ratio of 2.99, RSLS is valued rather cheaply. On top of this, RSLS is cheaper than 100% of the companies listed in the same industry.
Compared to an average Enterprise Value to EBITDA ratio of 17.45, RSLS is valued rather cheaply. On top of this, RSLS has a better ratio than 96% of the companies listed in the same industry.
RSLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Price/Book (0.22) VS Industry: 100% outperformed.
102.64
0.22
Enterprise Value/ EBITDA (0.19) VS Industry: 96% outperformed.
445.13
0.02
Growth
Growth Rating
The Earnings Per Share has grown by an nice 14.58% over the past year.
RSLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 218.17%.
The Revenue has been growing by 32.01% on average over the past 5 years. This is a very strong growth!
The Revenue is expected to grow by 36.64% on average over the next 5 years. This is a very strong growth
Based on estimates for the next 5 years, RSLS will show a small growth in Earnings Per Share. The EPS will grow by 7.41% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 14.58% | 55.27% | 27.91% | 14.76% | 7.41% |
| Revenue | 32.01% | 14.33% | 218.17% | 24.31% | 36.99% | 36.3% | 36.64% |
Health
Health Rating
A Current Ratio of 2.90 indicates that RSLS has no problem at all paying its short term obligations.
A Quick Ratio of 2.41 indicates that RSLS has no problem at all paying its short term obligations.
When comparing the Debt to Equity Ratio of 0.00 to an average industry Debt to Equity of 0.08, RSLS is way less dependent on financing that its industry peers.
The Piotroski-F score of RSLS is 4.00. This is a neutral score and indicates average health and profitability for RSLS.
Compared to an average industry Current Ratio of 4.06, RSLS is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 3.41, RSLS is worse placed to pay its short term obligations than its industry peers.
RSLS has an Altman-Z score of -20.60. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 2.30, RSLS is in worse financial state than most of its industry peers. 98% of its industry peers have a better Altman-Z score.
VS Industry
Debt/Equity (0) VS Industry: 68% outperformed.
12.60
0.00
Quick Ratio (2.41) VS Industry: 37% outperformed.
0.07
47.32
Current Ratio (2.9) VS Industry: 31% outperformed.
0.12
48.19
Altman-Z (-20.6) VS Industry: 2% outperformed.
-106.60
58.32
Dividend
Dividend Rating
No dividends for RSLS!.
RESHAPE LIFESCIENCES INC0.46
NASDAQ:RSLS (8/16/2022, 3:00:59 PM)-0.03 (-6.12%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Equipment & Supplies | ||
| Earnings (Last) | 08-15 2022-08-15/amc | Earnings (Next) | 11-09 2022-11-09 |
| Ins Owners | N/A | Inst Owners | 7% |
| Market Cap | 8.60M | Analysts | 82.5 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 0.67 | P/B | 0.22 |
| EV/EBITDA | 0.19 | ||
| ROA | -138.09% | ROE | N/A |
| PM | -509.2 | Asset Turnover | 0.27 |
| EPS 1Y | 14.58% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 37.14% |
| EPS Next Y | 55.27% | EPS Next 2Y | 27.91% |
| EPS Next 3Y | 14.76% | EPS Next 5Y | 7.41% |
| Revenue growth 1Y | 218.17% | Revenue growth 3Y | 14.33% |
| Revenue growth 5Y | 32.01% | Revenue growth Q2Q | -24.25% |
| Revenue Next Year | 24.31% | Revenue Next 2Y | 36.99% |
| Revenue Next 3Y | 36.3% | Revenue Next 5Y | 36.64% |
| Current Ratio | 2.9 | Quick Ratio | 2.41 |
| Altman-Z | -20.6 | F-Score | 4 |
| Debt/Equity | 0 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA